These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Funahashi Y; Okamoto K; Adachi Y; Semba T; Uesugi M; Ozawa Y; Tohyama O; Uehara T; Kimura T; Watanabe H; Asano M; Kawano S; Tizon X; McCracken PJ; Matsui J; Aoshima K; Nomoto K; Oda Y Cancer Sci; 2014 Oct; 105(10):1334-42. PubMed ID: 25060424 [TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma. Emambux S; Italiano A Expert Opin Pharmacother; 2017 Jun; 18(8):819-824. PubMed ID: 28468516 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550 [TBL] [Abstract][Full Text] [Related]
14. Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma. Seetharam M; Kolla KR; Chawla SP Future Oncol; 2018 Jul; 14(16):1531-1545. PubMed ID: 29411654 [TBL] [Abstract][Full Text] [Related]
15. Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer. Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M Anticancer Res; 2018 May; 38(5):2929-2938. PubMed ID: 29715119 [TBL] [Abstract][Full Text] [Related]
16. Multifarious targets beyond microtubules-role of eribulin in cancer therapy. Seshadri P; Deb B; Kumar P Front Biosci (Schol Ed); 2021 Dec; 13(2):157-172. PubMed ID: 34879468 [TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment. Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Takahashi K; Fujita H; Shibutani M; Amano R; Takashima T; Tomita S; Hirakawa K; Ohira M BMC Cancer; 2020 Dec; 20(1):1215. PubMed ID: 33302911 [TBL] [Abstract][Full Text] [Related]
18. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study. Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Togo S; Shimizu H; Saito M J Transl Med; 2018 Oct; 16(1):287. PubMed ID: 30342534 [TBL] [Abstract][Full Text] [Related]
19. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cortes J; Montero AJ; Glück S Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727 [TBL] [Abstract][Full Text] [Related]
20. Eribulin mesylate for the treatment of breast cancer. Cigler T; Vahdat LT Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]